Could Viking Therapeutics Become the Next Eli Lilly?

Viking Therapeutics (VKTX) is emerging as a potential competitor in the booming obesity treatment market, currently dominated by Eli Lilly's (LLY) Zepbound. Viking's VK2735, a dual GLP-1/GIP agonist, showed promising Phase 2 trial results with a 15% weight loss in 13 weeks, potentially outperforming existing therapies; however, the company's $3 billion valuation is small compared to industry leaders, and FDA approval is still pending, making it a speculative investment with significant long-term potential if further testing validates these results.

Analysis

The obesity treatment market, estimated at $100 billion, is experiencing significant expansion, prominently featuring Eli Lilly (LLY) whose Zepbound drug has contributed to a 400% stock return over the past five years. Eli Lilly, a healthcare major with a $685 billion market capitalization and $45 billion in 2024 revenue, demonstrated strong financial health with a 45% year-over-year increase in first-quarter revenue to $12.7 billion and a 29% rise in earnings per share, driven by its dual GLP-1/GIP agonist tirzepatide (marketed as Mounjaro and Zepbound), which has shown approximately 21% patient weight loss over 72 weeks. Against this backdrop, Viking Therapeutics (VKTX), a clinical-stage biotech company valued at $3 billion and yet to commercialize any product, is developing VK2735, a novel dual GLP-1/GIP agonist. Promising Phase 2 VENTURE trial data for VK2735 indicated a 15% weight loss in 13 weeks, suggesting potentially superior rapid efficacy and a favorable safety profile with mostly mild to moderate side effects compared to existing therapies. Viking Therapeutics reported $852 million in cash reserves and no debt as of March 31, and has proactively secured manufacturing capacity for up to 100 million autoinjectors and other product forms annually, signaling preparedness for potential commercialization. However, the path to U.S. Food and Drug Administration (FDA) approval for VK2735 remains lengthy and uncertain, categorizing VKTX as a highly speculative investment despite its disruptive potential in the GLP-1 market. The article conveys an overall positive yet speculative sentiment (sentiment score 0.45) regarding these developments, with a noted market impact score of 0.6.

Key Decisions for Investors

• Investors might consider Eli Lilly a foundational investment for exposure to the obesity therapeutic sector, given its proven market leadership, strong revenue growth, and the success of Zepbound.
• Viking Therapeutics presents a high-risk, high-reward opportunity; it may appeal to investors with a long-term investment horizon and a high tolerance for risk, who are betting on positive future clinical outcomes and eventual FDA approval for VK2735.
• Monitoring upcoming clinical trial readouts for Viking's VK2735 later this year is crucial, as these results will likely serve as significant catalysts for the stock.
• Considering the speculative nature of clinical-stage biotechnology firms and the article's mention that Viking Therapeutics was not among one analyst team's top 10 current buy recommendations, any investment in VKTX should be part of a well-diversified portfolio and follow careful due diligence.